| P50 | author | Mark Wainberg | Q3294273 |
| | Thibault Mesplède | Q40671705 |
| P2093 | author name string | Yingshan Han | |
| P2860 | cites work | Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence | Q26801286 |
| | Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication | Q27661671 |
| | Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1 | Q27684242 |
| | Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor | Q33797858 |
| | A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. | Q35667426 |
| | The promise and pitfalls of long-acting injectable agents for HIV prevention | Q36561375 |
| | Allosteric inhibition of HIV-1 integrase activity | Q36920004 |
| | Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. | Q37263531 |
| | Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. | Q37469579 |
| | Integrase strand transfer inhibitors in the management of HIV-positive individuals | Q38192022 |
| | Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences | Q38240347 |
| | Formulation and pharmacology of long-acting cabotegravir | Q38518434 |
| | Cabotegravir long-acting for HIV-1 prevention | Q38518446 |
| | Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection | Q38570500 |
| | Targeting Virus-host Interactions of HIV Replication | Q38577612 |
| | Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens | Q38813848 |
| | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial | Q40059801 |
| | Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults | Q40333725 |
| | Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam | Q41015337 |
| | Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial | Q41095343 |
| | The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge | Q41544436 |
| | Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults | Q41618857 |
| | Differential sensitivities of retroviruses to integrase strand transfer inhibitors | Q42017701 |
| | Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor | Q42260849 |
| | GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects | Q42678192 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| | phase II clinical trial | Q42824440 |
| P304 | page(s) | 1207-1213 | |
| P577 | publication date | 2017-09-28 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Investigational HIV integrase inhibitors in phase I and phase II clinical trials | |
| P478 | volume | 26 | |